BRAF and colorectal cancer: However, in contrast, the spartalizumab combination with D/T showed survival benefit potential for BRAF-mutant colorectal cancer patients, and a single-cell RNA sequencing analysis of this cohort revealed that more effective induction of tumor cell-intrinsic immune programs and MEK/ERK inhibition is associated with better clinical outcomes [121].